{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:17:23Z","timestamp":1774909043139,"version":"3.50.1"},"reference-count":72,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p> Asthma is a chronic inflammatory condition involving the airways with varying pathophysiological mechanisms, clinical symptoms and outcomes, generally controlled by conventional therapies including inhaled corticosteroids and long-acting \u03b2<jats:sub>2<\/jats:sub> agonists. However, these therapies are unable to successfully control symptoms in about 5\u201310% of severe asthma patients. Atopic asthma, characterized by high immunoglobulin (Ig)E or eosinophilia, represents about 50% of asthmatic patients. Interleukin (IL)-5 is the main cytokine responsible of activation of eosinophils, hence therapeutic strategies have been investigated and developed for clinical use. Biologics targeting IL-5 and its receptor (first mepolizumab and subsequently, reslizumab and benralizumab), have been recently approved and used as add-on therapy for severe eosinophilic asthma resulting in a reduction in the circulating eosinophil count, improvement in lung function and exacerbation reduction in asthma patients. Despite these biologics having been approved for stratified severe asthma patients that remain uncontrolled with high doses of conventional therapy, a number of patients may be eligible for more than one biologic. Presently, the lack of head-to-head studies comparing the biological agents among themselves and with conventional therapy make the choice of optimal therapy for each patient a challenge for clinicians. Moreover, discontinuation of these treatments, implications for efficacy or adverse events, in particular in long-term treatment, and needs for useful biomarkers are still matters of debate. In this review we evaluate to date, the evidence on mepolizumab that seems to demonstrate it is a well-tolerated and efficacious regimen for use in severe eosinophilic asthma, though more studies are still required. <\/jats:p>","DOI":"10.1177\/1753466618808490","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T07:22:28Z","timestamp":1540452148000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":67,"title":["Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience"],"prefix":"10.1177","volume":"12","author":[{"given":"Rosalia","family":"Emma","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania (CT), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaymin B.","family":"Morjaria","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Royal Brompton & Harefield Hospital Foundation Trust, Harefield Hospital, Hill End Road, Harefield, UK"},{"name":"Honorary Senior Clinical Lecturer, Respiratory Medicine, Imperial College, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Fuochi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, Catania (CT), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Polosa","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, Catania (CT), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-2080","authenticated-orcid":false,"given":"Massimo","family":"Caruso","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, Department of Clinical and Experimental Medicine, University of Catania, Via S. Sofia, 97, 95123 Catania (CT), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,25]]},"reference":[{"key":"bibr1-1753466618808490","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention, http:\/\/ginasthma.org\/wp-content\/uploads\/2016\/04\/GINA-2016-main-report_tracked.pdf (2016, accessed 9 May 2018)."},{"key":"bibr2-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2678"},{"key":"bibr3-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"bibr4-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1186\/s40733-016-0029-3"},{"key":"bibr5-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.048"},{"key":"bibr6-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02135-2016"},{"key":"bibr7-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000434"},{"key":"bibr8-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-017-1773-y"},{"key":"bibr9-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"bibr10-1753466618808490","first-page":"CD010834","volume":"9","author":"Farne HA","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr11-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00157-9"},{"key":"bibr12-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3300"},{"key":"bibr13-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010113231505"},{"key":"bibr14-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.017"},{"key":"bibr15-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.5.1085"},{"key":"bibr16-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01782-2017"},{"key":"bibr17-1753466618808490","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention, https:\/\/ginasthma.org\/wp-content\/uploads\/2018\/04\/wms-GINA-2018-report-tracked_v1.3.pdf (2018, accessed June 13, 2018)."},{"key":"bibr18-1753466618808490","unstructured":"National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma, https:\/\/www.nice.org.uk\/guidance\/ta431 (2017, accessed 13 June 2018)."},{"key":"bibr19-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.02.003"},{"key":"bibr20-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000284"},{"key":"bibr21-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000340"},{"key":"bibr22-1753466618808490","unstructured":"Scientific Discussion. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000606\/WC500057295.pdf (accessed 21 May 2018)."},{"key":"bibr23-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02803.x"},{"key":"bibr24-1753466618808490","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S107982"},{"key":"bibr25-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000251"},{"key":"bibr26-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03241.x"},{"key":"bibr27-1753466618808490","unstructured":"U.S. Food and Drug Administration, Center of Drug Evaluation and Research. Nucala - highlights of prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf (2015, accessed 13 August 2018)."},{"key":"bibr28-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"bibr29-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"bibr30-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"bibr31-1753466618808490","unstructured":"U.S. Food and Drug Administration. Nucala - highlights of prescribing information, www.fda.gov\/medwatch (2017, accessed August 13, 2018)."},{"key":"bibr32-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9"},{"key":"bibr33-1753466618808490","unstructured":"Open-label extension study to evaluate the long-term safety and efficacy of reslizumab (3.0 mg\/kg) as treatment for patients (12 through 75 years of age) with eosinophilic asthma - full text view - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01290887?term=NCT01290887&rank=1 (accessed 13 August 2018)."},{"key":"bibr34-1753466618808490","unstructured":"Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils - Full text view - ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02452190?term=NCT02452190&rank=1 (accessed 13 August 2018)."},{"key":"bibr35-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"bibr36-1753466618808490","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information \u2013 CINQAIR, www.fda.gov\/medwatch. (2016, accessed August 13, 2018)."},{"key":"bibr37-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.005"},{"key":"bibr38-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"bibr39-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"bibr40-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1038\/nature12526"},{"key":"bibr41-1753466618808490","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.87.463"},{"key":"bibr42-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-1-r3"},{"key":"bibr43-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.004"},{"key":"bibr44-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1208564"},{"key":"bibr45-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.105712"},{"key":"bibr46-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.042"},{"key":"bibr47-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2018.03.001"},{"key":"bibr48-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.11.029"},{"key":"bibr49-1753466618808490","doi-asserted-by":"publisher","DOI":"10.2146\/news150083"},{"key":"bibr50-1753466618808490","first-page":"321","volume":"5","author":"Gnanakumaran G","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"bibr51-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000183"},{"key":"bibr52-1753466618808490","unstructured":"U.S. Food and Drug Administration. FDA news release: FDA approves Nucala to treat severe asthma, https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/UCM471031_F (2015, accessed 1 July 2018)."},{"key":"bibr53-1753466618808490","unstructured":"GlaxoSmithKline. Mepolizumab (NUCALA) EU summary of product characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003860\/WC500198037.pdf (2015, accessed 1 July 2018)."},{"key":"bibr54-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03496-6"},{"key":"bibr55-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-789OC"},{"key":"bibr56-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-085OC"},{"key":"bibr57-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435"},{"key":"bibr58-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"bibr59-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"bibr60-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"bibr61-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30031-5"},{"key":"bibr62-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2016.11.006"},{"key":"bibr63-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.008"},{"key":"bibr64-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12853"},{"key":"bibr65-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1111\/all.12914"},{"key":"bibr66-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010834.pub2"},{"key":"bibr67-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.026"},{"key":"bibr68-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0689-2"},{"key":"bibr69-1753466618808490","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201312-454OC"},{"key":"bibr70-1753466618808490","first-page":"81","volume":"11","author":"Haldar P.","year":"2017","journal-title":"Biologics"},{"key":"bibr71-1753466618808490","volume":"13","author":"Poon AH","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"bibr72-1753466618808490","volume":"7","author":"Varricchi G","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618808490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753466618808490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753466618808490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:38:13Z","timestamp":1740821893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753466618808490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":72,"alternative-id":["10.1177\/1753466618808490"],"URL":"https:\/\/doi.org\/10.1177\/1753466618808490","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"article-number":"1753466618808490"}}